Can HIV-associated nephropathy (HIVAN) cause Rapidly Progressive Glomerulonephritis (RPGN) in days after starting antiretroviral therapy (ART)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 24, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

HIV-Associated Nephropathy: Clinical Presentation and Natural Course

HIVAN does NOT cause rapidly progressive glomerulonephritis (RPGN) within days after starting antiretroviral therapy; rather, ART dramatically slows disease progression and may improve renal function. 1, 2, 3

Signs and Symptoms of HIVAN

Classic HIVAN presents with:

  • Heavy proteinuria (often nephrotic-range) with extensive podocyte foot process effacement 4
  • Rapid decline in kidney function without treatment 2, 5
  • Occurs predominantly in Black patients between ages 20-64 years 5, 6
  • Strongly associated with severe immunosuppression and low CD4+ counts 2
  • Majority of patients have AIDS-defining conditions at diagnosis 5
  • Requires APOL1 high-risk genotypes (G1 and G2 variants) plus a "second-hit" event for disease manifestation 2

Natural Course Without Treatment

HIVAN is one of the most aggressive forms of kidney disease:

  • Progression to end-stage renal disease occurs within weeks to months without treatment 2, 5
  • Average time to ESRD is 3.9 months in untreated patients 2
  • GFR declines at 4.3 mL/min/month without antiretroviral therapy 2, 6
  • Renal survival is only 12.5% without treatment 2

Effect of Antiretroviral Therapy on Disease Course

ART dramatically improves outcomes rather than causing acute deterioration:

  • Time to ESRD increases from 3.9 months to 18.4 months with ART 2
  • GFR decline slows from 4.3 mL/min/month to 0.08 mL/min/month with treatment 2, 6
  • Renal survival improves from 12.5% to 18.1% with ART 2
  • ART should be initiated immediately in all patients with biopsy-proven HIVAN, regardless of CD4 count 4, 1, 3
  • Achieving HIV RNA suppression to <200 copies/mL is associated with improved outcomes 2

HIVAN Does Not Present as RPGN After Starting ART

The evidence clearly demonstrates that ART improves rather than worsens HIVAN. The disease naturally progresses rapidly over weeks to months when untreated, but this is the natural course of the disease itself, not a complication of starting therapy 2, 5. ART dramatically slows this progression and may even improve kidney function 6, 3.

Histopathology

Classic HIVAN is defined by:

  • Collapsing glomerulopathy with glomerular basement membrane collapse 4, 2
  • Hypertrophy and hyperplasia of glomerular epithelial cells forming "pseudocrescents" 4
  • Tubular microcyst formation 4, 2
  • Interstitial inflammation and tubular injury 4, 2
  • Diffuse podocyte foot process effacement on electron microscopy 4, 2

Critical Diagnostic Considerations

Kidney biopsy is essential because:

  • Up to 50% of HIV-positive patients with glomerular disease have lesions other than classic HIVAN 2, 7
  • The spectrum has shifted post-ART era toward immune complex glomerulonephritis, diabetic nephropathy, and non-collapsing FSGS 4, 7
  • Biopsy differentiates HIVAN from ART nephrotoxicity, immune complex disease, and comorbid conditions 4, 8
  • Classic HIVAN has the poorest 5-year kidney survival compared to other HIV-related kidney diseases 7

Common Pitfall to Avoid

Do not delay or withhold ART due to concerns about worsening kidney function. The evidence overwhelmingly demonstrates that early ART initiation benefits kidney outcomes in HIVAN, and modern antiretroviral regimens have improved safety profiles 1. The rapid progression seen in HIVAN is the natural course of untreated disease, not a consequence of starting therapy 2, 5.

References

Guideline

Antiretroviral Therapy Benefits for HIV-Associated Kidney Diseases

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Natural History and Treatment of HIV-Associated Nephropathy

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Antiretroviral therapy in the treatment of HIV-associated nephropathy.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2006

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Treatment of HIV-associated nephropathy.

Seminars in nephrology, 2000

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.